Hyaluronidase: the dissolving protocol every filler clinic needs

Hyaluronidase is the reason hyaluronic acid filler is the forgiving category of injectable: almost everything it does can be undone. It is also the drug at the centre of every filler emergency protocol, which means a clinic’s relationship with hyaluronidase says a great deal about how seriously it takes patient safety. This guide explains what it is, how emergency and elective dissolving differ, and why the protocol needs to exist long before anyone needs it.

What hyaluronidase is

Hyaluronidase (often shortened to hyalase) is an enzyme that breaks down hyaluronic acid, including the hyaluronic acid in dermal fillers. Injected into or around unwanted filler, it disperses the product, with visible change often beginning within hours and the full effect judged over the following days. It works on hyaluronic acid fillers only; it has no effect on non-HA products such as calcium hydroxylapatite or poly-L-lactic acid, which is one of the strongest arguments for choosing dissolvable filler in the first place.

In the UK, hyaluronidase is a prescription-only medicine. That matters practically: a prescriber must be involved in its supply and use, whether that is the practitioner themselves holding prescribing rights or a prescribing arrangement that genuinely stands up, meaning the prescriber has assessed the patient rather than signed at a distance. A clinic offering filler without a credible route to hyaluronidase is offering a treatment without its safety net.

Emergency versus elective dissolving

The two uses of hyaluronidase are clinically and operationally different, and conflating them causes problems.

Emergency dissolving is the response to a suspected vascular occlusion: filler in or compressing a blood vessel, threatening the skin or, in the worst periorbital cases, vision. Here, time matters more than almost anything else. The widely accepted position is that in a genuine vascular emergency, treatment proceeds urgently and the usual elective niceties, including patch testing, give way to the immediate threat. This is precisely why the protocol, the stock and the prescriber arrangement must already exist: an emergency is the wrong moment to discover the vial is out of date or the prescriber is on holiday.

Elective dissolving is everything else: migrated lip filler, an overfilled tear trough, lumps that have not settled, old product of unknown origin, or a patient who simply no longer wants what they have. Elective work is planned, consented and unhurried, and it follows the conventions below.

Allergy testing conventions for elective use

Hyaluronidase carries a recognised risk of allergic reaction, including, rarely, anaphylaxis. For elective dissolving, the common UK convention is a patch test: a small intradermal test dose, typically in the forearm, observed for a reaction before the treatment dose is given, with practice varying on the observation window. Conventions differ between training providers and prescribers, so follow the protocol your prescriber and insurer have agreed rather than treating any single approach as universal. What should not vary is the screening: ask specifically about previous hyaluronidase exposure and about bee and wasp venom allergy, which is relevant to sensitivity, and record the answers.

Patients should also hear two honest caveats before elective dissolving. The enzyme does not distinguish perfectly between filler and the body’s own hyaluronic acid, so some temporary deflation of the surrounding tissue is possible while natural HA replenishes. And dissolving is not always complete in one visit; older, cross-linked or layered product can need repeat sessions.

Why the emergency protocol must exist before it is needed

A vascular occlusion is rare, but the response window is short and the difference between a managed event and a disaster is preparation. Every clinic injecting HA filler should be able to answer yes, in writing, to all of the following:

• Stock. In-date hyaluronidase is on the premises whenever filler is injected, in sufficient quantity for a high-dose vascular protocol, and someone checks the expiry dates on a schedule.
• Prescriber. The prescribing route for emergency use is agreed in advance and works out of hours, not just on clinic days.
• Protocol. A written, rehearsed protocol covers recognition (pain, blanching, dusky or mottled skin, delayed capillary refill, visual symptoms), immediate management, dosing approach, escalation to emergency care and ophthalmology for visual symptoms, and who is called in what order.
• Anaphylaxis readiness. Adrenaline and the skills to use it are available, because hyaluronidase itself can cause allergic reactions, rarely including anaphylaxis.
• Patient-facing instructions. Every filler patient leaves with written red-flag guidance and a genuine out-of-hours contact route, because occlusions do not confine themselves to office hours.

If any answer is no, that is the week’s priority, ahead of marketing, ahead of new treatments.

Documenting dissolving events

Dissolving, emergency or elective, deserves the same documentation rigour as the original treatment, arguably more. The record should capture the indication and the assessment behind it, the consent conversation (a hyaluronidase consent form with itemised risks does the heavy lifting), the patch test and its result where performed, the prescriber involvement, the product, batch number, dilution and volumes used, photographs before and after, and the follow-up plan. For emergency use, contemporaneous timed notes matter enormously: when symptoms were recognised, when treatment was given, how the tissue responded, and when and where the patient was escalated. If the filler being dissolved was placed elsewhere, record what the patient knows about it, including the honest answer “product unknown”.

This is the kind of event where software proves its worth. AesthetiClinic keeps the consent, photographs, batch numbers and timed treatment notes on one patient record, versioned and retrievable on demand, so the documentation of your most serious clinical moments is complete without anyone reconstructing it afterwards. See the features overview.

The disappointment conversation

A meaningful share of elective dissolving is really the management of disappointment: filler from another clinic that migrated, an overdone look the patient has fallen out of love with, or a result that never matched the expectation. These consultations reward honesty and gentleness in equal measure. Confirm what the product is likely to be and whether it is dissolvable at all. Explain that dissolving is a treatment in its own right, with its own risks, its own cost and sometimes multiple visits. Set expectations about the interval before re-treatment, since most practitioners prefer to let tissue settle for a period before placing new filler. And resist the urge to criticise the previous injector; the patient needs a plan, not a verdict. Our guide to filler migration covers the commonest version of this conversation in detail.

Done well, dissolving is one of the most trust-building treatments a clinic offers. The patient arrives anxious about a thing they regret and leaves with evidence that this clinic fixes problems rather than creating them. Make sure the original filler consent points forwards to it too; our dermal filler consent form includes the hyaluronidase note for exactly that reason. Hyaluronidase is the reversal agent referenced throughout our dermal fillers guide.